A

American Institute of Research | Innovative Clinical Research Institute

Research site
(Unclaimed)
Location
15111 E. Whittier Boulevard Ste. 216, Whittier, California, United States of America

Site insights

Top conditions

Top treatments

Lenalidomide
Pembrolizumab
MT-3724
Gemcitabine
Docetaxel
Tyrosine
Pirtobrutinib
Carfilzomib
Atezolizumab
Tesetaxel

Parent organization

This site is a part of American Institute of Research

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

35 of 74 total trials

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combi...

Enrolling
Advanced Solid Tumors
HER2-positive Breast Cancer
Drug: ZN-A-1041 50mg BID
Drug: ZN-A-1041 200mg BID

This is a Phase 1/2, open-label, multicenter study designed to evaluate the maximum tolerated, safety, tolerability and PK of oral YY-15293 in patien...

Enrolling
Advanced Solid Tumor
Drug: YL-15293

The purpose of this study is to learn about the effects of a study medicine, WGI-0301 to find the best dose for treating solid tumors, and to see how...

Enrolling
Advanced Solid Tumors
Drug: WGI-0301

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303 in subjects with advanced solid tumo...

Enrolling
HER2-positive Advanced Solid Tumor
Drug: Pertuzumab Injection
Drug: Itraconazole

Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a n...

Active, not recruiting
Breast Cancer
Drug: DS-8201a

The purpose of this study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or ref...

Active, not recruiting
Lymphoma
Drug: Parsaclisib

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Bendamustine

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.

Active, not recruiting
Cutaneous Squamous Cell Carcinoma
Castration-resistant Prostate Cancer
Drug: Pembrolizumab
Drug: Nanrilkefusp Alfa

This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Tepotinib
Drug: Osimertinib

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of z...

Enrolling
DLBCL
Diffuse Large B-Cell Lymphoma
Biological: Zilovertamab vedotin
Drug: Gemcitabine
Locations recently updated

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Mezigdomide
Drug: Dexamethasone

The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life as...

Enrolling
Phlebotomy Dependent Polycythemia Vera
Drug: sapablursen

Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patie...

Active, not recruiting
Hand-Foot Skin Reaction (HFSR)
Drug: OQL011
Drug: Vehicle Ointment

This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time thi...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their cancer:* cannot b...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab
Drug: Trastuzumab deruxtecan

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab deruxtecan (T-DXd)
Drug: Ado-trastuzumab emtansine (T-DM1)

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, c...

Active, not recruiting
Nonsmall Cell Lung Cancer
NSCLC
Drug: Immune checkpoint inhibitors or docetaxel
Device: NovoTTF-200T

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior myelodyspl...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine
Locations recently updated

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R ver...

Enrolling
Myelodysplastic Syndromes
Biological: Epoetin Alfa
Biological: Luspatercept

Trial sponsors

Gilead Sciences logo
Incyte logo
Celgene logo
Daiichi Sankyo logo
Molecular Templates logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
K
Loxo Oncology logo
Merck KGaA (EMD Serono) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems